maybe you missed this post about the staggered intf/nucs strategy to get very high hbe and hbs seroconversions, i d go for this if intf fails.try to check if your doctors are aware of this strategy, in pisa they do since 2009
There are trials of using PegIFN beyond 48 weeks to 96 weeks. I forgot the details. You will often find HBeAg seroconversion after stopping PegIFN as the tail of benefit of Interferon seems to be long.
I copied below the DRAFT NICE guideline from England. It recommends 48 week of PEGIFN as the first treatment for all HBeAg+ve patients, followed by Tenofovir/Entecavir if no HBeAg seroconversion.
Please bear in mind, it is a draft and is in the open discussion phase.
Treatment sequence in adults with HBeAg-positive chronic hepatitis B and compensated liver disease
1.5.15 Offer a 48-week course of peginterferon alfa-2a as first-line treatment in adults with HBeAg-positive chronic hepatitis B and compensated liver disease.
1.5.16 Stop peginterferon alfa-2a 12 weeks after starting treatment if HBV DNA level has decreased by less than 2 log10 IU/ml and offer second-line treatment in line with recommendations 1.5.17 and 1.5.18.
1.5.17 Offer tenofovir disoproxil as second-line treatment to people who do not undergo HBeAg seroconversion after first-line treatment with peginterferon alfa-2a.
1.5.18 Offer entecavir as an alternative second-line treatment to people who cannot tolerate tenofovir disoproxil or if it is contraindicated.
1.5.19 In people taking tenofovir disoproxil who have detectable HBV DNA at 48 weeks of treatment and no history of lamivudine resistance, consider adding lamivudine to tenofovir disoproxil. In people with a history of lamivudine resistance, consider adding entecavir to tenofovir disoproxil.
1.5.20 Consider stopping nucleoside or nucleotide analogue treatment 12 months after HBeAg seroconversion in people without cirrhosis.
1.5.21 Do not stop nucleoside or nucleotide analogue treatment 12 months after HBeAg seroconversion in people with cirrhosis.
do not know how long this "tail" is... thx for the draft but i do not think it'd be effordable to me.. anyhow this is the 2nd ifn course I do... the first one was stopped 6month after start as not responding..
I think you are missing the point of the draft. You already had 48 weeks of PegIFN with no HBeAg seroconversion, so according to the draft, you should stop PegIFN, then continue with Tenofovir/Entecavir(1.5.17, 1.5.18) unitil HBeAg seroconversion, then can consider stopping Tenofovir/Entecavir 12 months after HBeAg seroconversion(1.5.20).
Ok. Your method is based on Stef2011's recommendation. It's aim is for a complete cure. The NICE guideline and others are aimed at controlling the virus - keeping ALT normal and hbvdna as low as possible.
yes you got the point stef..i'm trying to realize what is really worth for the liver as my fibrosys is F0 almost...
anyhow i still struggle to understand if one can be eag +ve all life lonf or sooner or later (even if with falres/liver damages) eag -ve is the natural outcome of chornic hbv..
i know there're several metohd to keep und dna for years but at my age 27yo it does not seem to be the best solution as we do not know so far which sides tdf/etv may have after 30/40 years of 1 day pill...
becoming hbeag neg off therapy is worsening and not imrpving wth our genotype D
hbeag will change before 30yo for sure but this wont be an imrovment for you, the key is getting hbeag neg without the mutations and keep hbv in check for a long time
my sister is also not suggested any therapy since fibrosis is zero, we have probably less corrupted doctors in italy so antivirals are actually prescribed only when needed, that s too say damaged liver or older age
Here is a study that used 60 weeks of pegIFN. Note the low criteria for "SVR" at followup..Less than 20000 copies of HBV DNA...
Am J Gastroenterol. 2007 Dec;102(12):2718-23. Epub 2007 Jul 27.
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Gish RG, Lau DT, Schmid P, Perrillo R.
SourceDivision of Hepatology and Complex Gastroenterology, California Pacific Medical Center, San Francisco, California, USA.
OBJECTIVES: Forty-eight weeks of peginterferon alfa-2a is the approved regimen for chronic hepatitis B (CHB). Standard interferon is more effective for hepatitis B e antigen (HBeAg)-negative CHB when given for longer than 1 yr. This study evaluated peginterferon alfa-2a for 60 wk, alone or in combination with lamivudine.
METHODS: Thirteen patients with HBeAg-negative CHB received peginterferon alfa-2a (180 microg/week) for 60 wk or peginterferon alfa-2a (180 microg/week) for 12 wk followed by 48 wk of peginterferon alfa-2a plus lamivudine. The primary end point, sustained virologic response (SVR), was defined as a reduction in hepatitis B virus deoxyribonucleic acid (HBV DNA) of >or=2 log10 copies/mL and HBV DNA90% decrease in HBsAg concentration at week 60, including 3 with undetectable HBV DNA at week 84 and a fourth who met criteria for SVR.
CONCLUSIONS: Sixty weeks of peginterferon alfa-2a with or without lamivudine resulted in a higher rate of SVR compared to historical controls with HBeAg-negative CHB treated with 48 wk of pegylated interferon. Larger studies are necessary to assess if longer duration therapy is more effective than the standard regimen and results in a greater decline in HBsAg concentration.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.